Ertapenem_NP versus_FW Ceftriaxone_NP Followed_NP by_IN Appropriate_NP Oral_NP Therapy_NN for_IN Treatment_NP of_IN Complicated_NP Urinary_NP Tract_NP Infections_NNS in_IN Adults_NNS :_: Results_NNS of_IN a_DT Prospective_JJ ,_, Randomized_NP ,_, Double-Blind_NP Multicenter_NP Study_NP The_DT efficacy_NN and_CC safety_NN of_IN intravenous_JJ (_( i.v._JJ )_) ertapenem_NN (_( 1_CD g_NN once_IN a_DT day_NN )_) with_IN the_DT option_NN to_TO switch_VB to_TO an_DT oral_JJ agent_NN for_IN treatment_NN of_IN adults_NNS with_IN complicated_JJ urinary_JJ tract_NN infections_NNS (_( UTIs_NP )_) were_VBD compared_VBN with_IN that_DT of_IN i.v._JJ ceftriaxone_NN (_( 1_CD g_NN daily_JJ )_) with_IN the_DT same_JJ oral_JJ switch_NN option_NN in_IN a_DT multicenter_NN ,_, double-blind_JJ ,_, prospective_JJ ,_, randomized_VBN study_NN ._SENT At_IN entry_NN ,_, 592_CD patients_NNS were_VBD assigned_VBN to_TO one_CD of_IN two_CD strata_NNS :_: acute_JJ pyelonephritis_NN or_CC other_JJ complicated_JJ UTI_NN without_IN acute_JJ pyelonephritis_NN ._SENT After_IN a_DT minimum_NN of_IN 3_CD days_NNS ,_, patients_NNS could_MD be_VB switched_VBN to_TO an_DT oral_JJ antimicrobial_JJ agent_NN ._SENT A_DT total_NN of_IN 159_CD patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 171_CD patients_NNS in_IN the_DT ceftriaxone_NN group_NN were_VBD microbiologically_RB evaluable_JJ ._SENT Approximately_RB 95_CD %_NN of_IN patients_NNS in_IN each_DT treatment_NN group_NN were_VBD switched_VBN to_TO oral_JJ therapy_NN ._SENT The_DT most_RBS common_JJ pathogens_NNS were_VBD Escherichia_NP coli_NNS and_CC Klebsiella_NP pneumoniae_NNS ._SENT At_IN the_DT primary_JJ efficacy_NN endpoint_NN 5_CD to_TO 9_CD days_NNS after_IN treatment_NN ,_, 91.8_CD %_NN of_IN patients_NNS who_WP received_VBD ertapenem_NN and_CC 93.0_CD %_NN of_IN those_DT who_WP received_VBD ceftriaxone_NP had_VBD a_DT favorable_JJ microbiological_JJ response_NN (_( 95_CD %_NN confidence_NN interval_NN for_IN the_DT difference_NN ,_, adjusting_VBG for_IN strata_NNS ,_, -7.6_CD to_TO 5.1_CD %_NN )_) ,_, indicating_VBG that_IN outcomes_NNS in_IN the_DT two_CD treatment_NN groups_NNS were_VBD equivalent_JJ ._SENT Microbiological_JJ success_NN rates_NNS for_IN the_DT two_CD treatment_NN groups_NNS were_VBD similar_JJ when_WRB compared_VBN by_IN stratum_NN and_CC also_RB by_IN severity_NN of_IN infection_NN ._SENT The_DT frequency_NN and_CC severity_NN of_IN drug-related_JJ adverse_JJ events_NNS were_VBD generally_RB similar_JJ in_IN both_DT treatment_NN groups_NNS ._SENT In_IN this_DT study_NN ,_, ertapenem_NN was_VBD as_RB effective_JJ as_IN ceftriaxone_NN for_IN the_DT initial_JJ treatment_NN of_IN complicated_JJ UTIs_NN in_IN adults_NNS ,_, was_VBD generally_RB well_RB tolerated_VBN ,_, and_CC had_VBD a_DT similar_JJ overall_JJ safety_NN profile_NN ._SENT Urinary_JJ tract_NN infections_NNS (_( UTIs_NP )_) are_VBP responsible_JJ for_IN over_IN 7_CD million_CD physician_NN office_NN visits_NNS in_IN the_DT United_NP States_NPS each_DT year_NN ._SENT Most_JJS of_IN these_DT are_VBP uncomplicated_JJ infections_NNS of_IN the_DT urinary_JJ bladder_NN in_IN otherwise_RB healthy_JJ young_JJ women_NNS and_CC are_VBP easily_RB managed_VBN with_IN short-term_JJ antimicrobial_JJ therapy_NN ._SENT Treatment_NN of_IN complicated_JJ UTIs_NN ,_, however_RB ,_, is_VBZ generally_RB less_RBR successful_JJ ._SENT Ten_CD to_TO 14_CD days_NNS of_IN therapy_NN with_IN an_DT agent_NN active_JJ against_IN a_DT more_RBR extensive_JJ list_NN of_IN gram-negative_JJ bacilli_NNS is_VBZ recommended_VBN ._SENT For_IN serious_JJ infections_NNS ,_, initial_JJ empirical_JJ therapy_NN with_IN a_DT broad-spectrum_NN parenteral_JJ antimicrobial_JJ agent_NN followed_VBN by_IN an_DT oral_JJ agent_NN to_TO which_WDT the_DT responsible_JJ uropathogen_NN is_VBZ susceptible_JJ has_VBZ become_VBN standard_JJ therapy_NN (_( ,_, -_: )_) ._SENT Follow-up_NN urine_NN cultures_NNS are_VBP important_JJ because_IN bacterial_JJ eradication_NN is_VBZ more_RBR difficult_JJ to_TO achieve_VB ,_, and_CC recurrence_NN several_JJ weeks_NNS posttherapy_NN is_VBZ not_RB uncommon_JJ ._SENT Ertapenem_NP (_( formerly_RB MK-0826_NP ;_: Merck_NP &_CC Co._NP ,_, Inc._NP )_) is_VBZ a_DT once_RB a_DT day_NN parenteral_JJ beta-lactam_NN agent_NN with_IN excellent_JJ in_IN vitro_NN activity_NN against_IN many_JJ gram-positive_JJ and_CC gram-negative_JJ aerobes_NNS and_CC anaerobes_NNS generally_RB associated_VBN with_IN community-acquired_JJ infections_NNS ,_, including_VBG most_JJS members_NNS of_IN the_DT family_NN Enterobacteriaceae_NNS ,_, pathogens_NNS most_RBS commonly_RB responsible_JJ for_IN UTIs_NP ._SENT Ertapenem_NP is_VBZ not_RB indicated_VBN for_IN Pseudomonas_NP aeruginosa_NP or_CC enterococci_NP ,_, which_WDT are_VBP more_JJR often_RB associated_VBN with_IN nosocomial_JJ infections_NNS ._SENT The_DT objectives_NNS of_IN this_DT study_NN were_VBD to_TO compare_VB the_DT efficacy_NN ,_, tolerability_NN ,_, and_CC safety_NN of_IN 1_CD g_NN of_IN ertapenem_NN once_IN a_DT day_NN with_IN those_DT of_IN 1_CD g_NN of_IN ceftriaxone_NN once_IN a_DT day_NN ,_, both_CC followed_VBD by_IN optional_JJ oral_JJ therapy_NN ,_, for_IN the_DT treatment_NN of_IN adult_JJ patients_NNS with_IN complicated_JJ UTIs_NP ._SENT (_( These_DT data_NNS were_VBD presented_VBN in_IN part_NN at_IN the_DT 41st_JJ Interscience_NN Conference_NN on_IN Antimicrobial_JJ Agents_NNS and_CC Chemotherapy_NN ,_, Chicago_NP ,_, Ill._NP ,_, 17_CD December_NP 2001_CD ._SENT )_) Patients_NPS ._SENT |_SYM Patients_NPS aged_VBN >=18_NN years_NNS with_IN a_DT complicated_JJ UTI_NN (_( i.e._FW ,_, acute_JJ pyelonephritis_NN ,_, UTI_NP in_IN men_NNS ,_, or_CC UTI_NP associated_VBN with_IN obstruction_NN ,_, foreign_JJ bodies_NNS ,_, or_CC urologic_JJ abnormalities_NNS )_) were_VBD eligible_JJ for_IN the_DT study_NN if_IN they_PP required_VBD initial_JJ parenteral_JJ antimicrobial_JJ therapy_NN and_CC if_IN the_DT infection_NN was_VBD caused_VBN by_IN a_DT pathogen_NN susceptible_JJ to_TO the_DT study_NN drugs_NNS ._SENT Criteria_NNS for_IN acute_JJ pyelonephritis_NN included_VBD fever_NN ,_, flank_NN pain_NN or_CC costovertebral_JJ angle_NN tenderness_NN ,_, pyuria_NN (_( >=10_JJ white_JJ blood_NN cells_NNS )_) ,_, and_CC positive_JJ urine_NN culture_NN (_( >=105_NP CFU_NP of_IN a_DT uropathogen/ml_NN )_) within_IN 48_CD h_NN of_IN enrollment_NN ._SENT Criteria_NNS for_IN other_JJ complicated_JJ UTIs_NN were_VBD signs_NNS or_CC symptoms_NNS of_IN UTI_NP ,_, pyuria_NN ,_, and_CC positive_JJ urine_NN culture_NN in_IN a_DT male_NN ;_: female_JJ patients_NNS were_VBD additionally_RB required_VBN to_TO have_VB either_RB an_DT indwelling_VBG catheter_NN ,_, current_JJ bladder_NN catheterization_NN or_CC instrumentation_NN of_IN the_DT urinary_JJ tract_NN ,_, or_CC functional_JJ or_CC anatomical_JJ abnormality_NN of_IN the_DT urinary_JJ tract_NN ._SENT Patients_NNS with_IN any_DT of_IN the_DT following_VBG were_VBD excluded_VBN from_IN the_DT study_NN :_: pregnancy_NN or_CC lactation_NN in_IN women_NNS ,_, history_NN of_IN serious_JJ allergy_NN to_TO study_NN therapy_NN (_( patients_NNS with_IN a_DT history_NN of_IN mild_JJ rash_NN to_TO beta-lactams_NNS could_MD be_VB enrolled_VBN )_) ,_, complete_JJ obstruction_NN of_IN the_DT urinary_JJ tract_NN ,_, perinephric_JJ or_CC intrarenal_JJ abscess_NN ,_, prostatitis_NN ,_, any_DT rapidly_RB progressive_JJ disease_NN ,_, immune-compromising_VBG illness_NN or_CC therapy_NN ,_, the_DT need_NN for_IN concomitant_JJ antimicrobials_NNS ,_, acute_JJ hepatic_JJ failure_NN ,_, requirement_NN for_IN peritoneal_JJ dialysis_NN or_CC hemodialysis_NN ,_, treatment_NN with_IN a_DT systemic_JJ antimicrobial_JJ agent_NN for_IN >=24_JJ h_NN within_IN 72_CD h_NN prior_JJ to_TO the_DT baseline_JJ urine_NN culture_NN ,_, creatinine_NN clearance_NN of_IN <30_ml/min, 6_CD times_NNS the_DT upper_JJ limit_NN of_IN normal_JJ (_( ULN_NP )_) ,_, bilirubin_NN or_CC alkaline_JJ phosphatase_NN levels_NNS of_IN >3_NN times_CC the_DT ULN_NP ,_, absolute_JJ neutrophil_JJ count_NN of_IN <=1,000_NN per_IN mul_NN ,_, platelet_NN concentration_NN of_IN <75,000_NN per_IN mul_NN ,_, hematocrit_NN level_NN of_IN <25%,_or 1.5_CD times_NNS the_DT ULN_NN ._SENT Study_NN design_NN and_CC antimicrobial_JJ therapy_NN ._SENT |_SYM This_DT prospective_JJ ,_, double-blind_JJ (_( with_IN sponsor_NN blinding_NN )_) ,_, randomized_VBD ,_, multicenter_NN study_NN was_VBD conducted_VBN from_IN April_NP 1998_CD to_TO February_NP 2000_CD ._SENT Written_JJ consent_NN was_VBD obtained_VBN from_IN all_DT patients_NNS ,_, and_CC the_DT institutional_JJ review_NN board_NN at_IN each_DT participating_VBG site_NN approved_VBD the_DT protocol_NN ._SENT Eligible_JJ patients_NNS from_IN 31_CD centers_NNS in_IN the_DT United_NP States_NPS ,_, Central_NP and_CC South_NP America_NP ,_, and_CC Europe_NP were_VBD stratified_VBN to_TO pyelonephritis_NN (_( with_IN or_CC without_IN an_DT abnormality_NN of_IN the_DT urinary_JJ tract_NN )_) ,_, or_CC other_JJ complicated_JJ UTI_NN without_IN acute_JJ pyelonephritis_NN ._SENT Equal_JJ randomization_NN to_TO one_CD of_IN the_DT two_CD treatment_NN arms_NNS was_VBD accomplished_VBN by_IN using_VBG a_DT computer-generated_JJ random_JJ number_NN allocation_NN schedule_NN ._SENT Both_DT ertapenem_NN and_CC ceftriaxone_NN were_VBD given_VBN once_IN a_DT day_NN as_IN a_DT 1-g_JJ intravenous_JJ (_( i.v._JJ )_) dose_NN infused_VBN over_IN 30_CD min_NN ._SENT To_TO avoid_VB unblinding_NN due_JJ to_TO slight_JJ color_NN differences_NNS between_IN the_DT study_NN drugs_NNS ,_, patients_NNS also_RB received_VBD a_DT second_JJ color-matched_JJ saline_JJ placebo_NN infusion_NN ._SENT After_IN at_IN least_JJS 2_CD days_NNS of_IN hospital_NN or_CC clinic-based_JJ infusion_NN therapy_NN ,_, study_NN therapy_NN could_MD be_VB completed_VBN in_IN the_DT hospital_NN ,_, a_DT clinic_NN ,_, or_CC at_IN home_NN ._SENT Consistent_JJ with_IN current_JJ pyelonephritis_NN treatment_NN guidelines_NNS ,_, at_IN the_DT investigator_NN 's_POS discretion_NN and_CC after_IN a_DT minimum_NN of_IN 3_CD days_NNS of_IN i.v._JJ therapy_NN ,_, patients_NNS could_MD be_VB switched_VBN to_TO oral_JJ ciprofloxacin_NNS (_( 500_CD mg_NN twice_RB daily_JJ )_) if_IN they_PP were_VBD afebrile_JJ ;_: nausea_NN and_CC vomiting_NN had_VBD resolved_VBN ;_: signs_NNS ,_, symptoms_NNS ,_, and_CC leukocytosis_NN had_VBD improved_VBN ;_: and_CC a_DT urine_NN culture_NN was_VBD obtained_VBN ._SENT Other_JJ oral_JJ agents_NNS were_VBD permitted_VBN if_IN the_DT patient_NN could_MD not_RB tolerate_VB ciprofloxacin_NN or_CC if_IN the_DT causal_JJ pathogen_NN was_VBD resistant_JJ ._SENT The_DT suggested_JJ total_JJ duration_NN of_IN i.v._JJ plus_CC optional_JJ oral_JJ therapy_NN was_VBD 10_CD to_TO 14_CD days_NNS ._SENT Clinical_JJ assessments_NNS ._SENT |_SYM Patients_NPS were_VBD evaluated_VBN within_IN 24_CD h_NN of_IN enrollment_NN and_CC daily_RB thereafter_RB while_IN on_IN parenteral_JJ study_NN therapy_NN ._SENT The_DT clinical_JJ response_NN was_VBD measured_VBN on_IN day_NN 3_CD to_TO 5_CD of_IN parenteral_JJ therapy_NN ,_, at_IN the_DT discontinuation_NN of_IN i.v._JJ therapy_NN (_( DCIV_NP )_) ,_, 5_CD to_TO 9_CD days_NNS posttherapy_NN (_( test_NN of_IN cure_NN [_SYM TOC_NP ]_SYM visit_NN )_) ,_, and_CC 4_CD to_TO 6_CD weeks_NNS posttherapy_NN (_( late_JJ follow-up_NN [_SYM LFU_NP ]_SYM )_) ._SENT Each_DT infection_NN was_VBD assessed_VBN prior_RB to_TO unblinding_JJ and_CC considered_VBN severe_JJ if_IN there_EX was_VBD bacteremia_NN ,_, signs_NNS of_IN sepsis_NN (_( diastolic_JJ blood_NN pressure_NN of_IN <60_mm 101C_NP ,_, chills_NNS ,_, nausea_NN or_CC vomiting_NN ,_, or_CC a_DT white_JJ blood_NN cell_NN count_NN of_IN >=15,000_NN per_IN mul_NN ._SENT Microbiological_JJ assessments_NNS ._SENT |_SYM Urine_NP culture_NN with_IN quantitation_NN and_CC blood_NN culture_NN were_VBD performed_VBN at_IN the_DT baseline_NN ._SENT All_DT isolates_NNS were_VBD identified_VBN at_IN the_DT site_NN laboratory_NN ,_, and_CC pathogens_NNS were_VBD tested_VBN for_IN in_IN vitro_NN susceptibility_NN to_TO ertapenem_NN ,_, ceftriaxone_NN ,_, and_CC ciprofloxacin_NN ,_, following_VBG the_DT guidelines_NNS of_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NPS ._SENT Microbiologic_JJ efficacy_NN was_VBD assessed_VBN at_IN each_DT time_NN point_NN by_IN quantitative_JJ urine_NN culture_NN ._SENT After_IN at_IN least_JJS 48_CD h_NN of_IN study_NN i.v._JJ therapy_NN ,_, failure_NN was_VBD defined_VBN as_IN a_DT urine_NN culture_NN with_IN a_DT >=104-CFU/ml_NN concentration_NN of_IN any_DT uropathogen_NN present_NN in_IN the_DT admission_NN culture_NN at_IN a_DT concentration_NN of_IN >=105_NP CFU/ml_NP ._SENT Microbiologic_JJ responses_NNS during_IN therapy_NN and_CC at_IN the_DT TOC_NP visit_NN were_VBD defined_VBN as_IN eradication_NN (_( the_DT urine_NN culture_NN showed_VBD that_IN a_DT uropathogen_NN present_NN at_IN a_DT concentration_NN of_IN >=105_JJ CFU/ml_NN at_IN entry_NN was_VBD reduced_VBN to_TO a_DT concentration_NN of_IN <104_CFU/ml), =104_NP CFU_NP of_IN an_DT original_JJ uropathogen/ml_NN )_) ,_, persistence_NN with_IN acquisition_NN of_IN resistance_NN ,_, superinfection_NN (_( the_DT urine_NN culture_NN grew_VBD >=105_NP CFU_NP of_IN a_DT uropathogen_NN other_JJ than_IN the_DT baseline_JJ pathogen_NN during_IN therapy_NN per_IN ml_NN )_) ,_, or_CC new_JJ infection_NN (_( >=105_NP CFU_NP of_IN a_DT pathogen_NN other_JJ than_IN the_DT baseline_JJ pathogen_NN cultured_VBN after_IN completion_NN of_IN therapy_NN per_IN ml_NN )_) ._SENT Additional_JJ responses_NNS at_IN LFU_NP were_VBD recurrence_NN (_( eradication_NN at_IN TOC_NP but_CC >=104_NP CFU_NP of_IN an_DT original_JJ uropathogen/ml_NN at_IN LFU_NP )_) and_CC recurrence_NN with_IN acquisition_NN of_IN resistance_NN ._SENT Populations_NNS for_IN analysis_NN ._SENT |_SYM The_DT treated_VBN population_NN included_VBD patients_NNS who_WP received_VBD at_IN least_JJS one_CD dose_NN of_IN study_NN therapy_NN ._SENT The_DT microbiologic_JJ modified_JJ intent-to-treat_NNS (_( MITT_NP )_) population_NN included_VBD patients_NNS who_WP received_VBD at_IN least_JJS one_CD dose_NN of_IN i.v._JJ therapy_NN ,_, had_VBD a_DT baseline_JJ uropathogen_NN in_IN any_DT quantity_NN ,_, and_CC had_VBD a_DT follow-up_NN quantitative_JJ urine_NN culture_NN after_IN DCIV_NP ._SENT Microbiologically_RB evaluable_JJ patients_NNS had_VBD to_TO meet_VB the_DT following_VBG criteria_NNS :_: clinical_JJ evidence_NN of_IN a_DT UTI_NP ,_, baseline_JJ urine_NN pathogen_NN at_IN a_DT concentration_NN of_IN >=105_NP CFU/ml_NP (_( >=104_NP CFU/ml_NP if_IN the_DT patient_NN was_VBD bacteremic_JJ )_) ,_, at_IN least_JJS one_CD baseline_NN pathogen_NN susceptible_JJ or_CC intermediate_JJ to_TO both_DT i.v._JJ study_NN antimicrobials_NNS ,_, and_CC a_DT urine_NN culture_NN at_IN the_DT TOC_NP visit_NN ._SENT The_DT LFU_NP evaluable_JJ population_NN included_VBD evaluable_JJ patients_NNS successfully_RB treated_VBN at_IN the_DT TOC_NP visit_NN who_WP also_RB had_VBD a_DT follow-up_NN assessment_NN within_IN the_DT LFU_NP window_NN ._SENT Efficacy_NN variables_NNS ._SENT |_SYM The_DT primary_JJ efficacy_NN variable_NN was_VBD the_DT assessment_NN of_IN bacteriologic_JJ eradication_NN in_IN the_DT microbiologically_RB evaluable_JJ population_NN at_IN the_DT TOC_NP visit_NN ._SENT Additional_JJ assessments_NNS were_VBD the_DT microbiologic_JJ response_NN rates_NNS in_IN the_DT MITT_NP population_NN and_CC the_DT clinical_JJ and_CC microbiologic_JJ responses_NNS in_IN evaluable_JJ patients_NNS at_IN DCIV_NP ._SENT Microbiologic_JJ recurrence_NN and_CC clinical_JJ relapse_NN were_VBD also_RB assessed_VBN in_IN evaluable_JJ patients_NNS at_IN the_DT LFU_NP visit_NN ._SENT Safety_NN and_CC tolerability_NN assessment_NN ._SENT |_SYM Patients_NNS in_IN the_DT treated_VBN population_NN were_VBD monitored_VBN for_IN adverse_JJ experiences_NNS daily_JJ during_IN parenteral_JJ therapy_NN and_CC for_IN 14_CD days_NNS after_IN all_DT study_NN therapy_NN (_( parenteral_JJ plus_CC oral_JJ )_) was_VBD completed_VBN ._SENT The_DT investigator_NN categorized_VBD the_DT intensity_NN of_IN the_DT adverse_JJ event_NN (_( mild_JJ ,_, moderate_JJ ,_, or_CC severe_JJ )_) and_CC the_DT likelihood_NN of_IN its_PP$ relation_NN to_TO the_DT study_NN drug_NN (_( definitely_RB not_RB ,_, probably_RB not_RB ,_, possibly_RB ,_, probably_RB ,_, or_CC definitely_RB )_) ._SENT The_DT tolerability_NN of_IN the_DT parenteral_JJ study_NN drug_NN at_IN the_DT local_JJ infusion_NN site_NN was_VBD evaluated_VBN by_IN the_DT investigator_NN daily_RB ._SENT Statistical_JJ analyses_NNS ._SENT |_SYM The_DT study_NN was_VBD designed_VBN to_TO test_VB for_IN equivalence_NN in_IN the_DT efficacy_NN of_IN the_DT ertapenem_NN and_CC ceftriaxone_NN microbiologically_RB evaluable_JJ treatment_NN groups_NNS ._SENT The_DT sample_NN size_NN (_( minimum_JJ of_IN 150_CD evaluable_JJ patients_NNS per_IN group_NN )_) was_VBD calculated_VBN with_IN Blackwelder_NP 's_POS formula_NN and_CC for_IN the_DT following_VBG values_NNS :_: alpha_NN ,_, 0.025_CD ;_: beta_NN ,_, 0.20_CD ;_: and_CC the_DT expected_VBN response_NN rate_NN in_IN both_DT groups_NNS ,_, 90_CD %_NN ._SENT In_IN accordance_NN with_IN the_DT Food_NP and_CC Drug_NP Administration_NP 's_POS guidance_NN for_IN industry_NN on_IN developing_VBG antimicrobial_JJ drugs_NNS --_: -General_JJ Consideration_NN for_IN Clinical_NP Trials_NP (_( July_NP 1998_CD )_) ,_, equivalence_NN for_IN this_DT study_NN was_VBD determined_VBN by_IN the_DT 95_CD %_NN (_( two-sided_JJ )_) confidence_NN interval_NN (_( CI_NP )_) for_IN the_DT difference_NN in_IN response_NN rates_NNS between_IN the_DT two_CD treatment_NN groups_NNS (_( ertapenem_NN minus_CC ceftriaxone_NN )_) ._SENT If_IN the_DT observed_JJ response_NN rate_NN in_IN the_DT comparator_NN group_NN was_VBD >90_JJ %_NN ,_, for_IN equivalence_NN to_TO be_VB demonstrated_VBN ,_, the_DT CI_NP of_IN the_DT difference_NN had_VBD to_TO contain_VB zero_NN and_CC its_PP$ lower_JJR limit_NN could_MD not_RB be_VB less_JJR than_IN -10_CD percentage_NN points_NNS ._SENT CIs_NNS about_IN the_DT difference_NN were_VBD calculated_VBN by_IN using_VBG the_DT normal_JJ approximation_NN to_TO the_DT binomial_JJ distribution_NN and_CC were_VBD adjusted_VBN for_IN strata_NNS by_IN using_VBG the_DT Cochran-Mantel-Haenzel_NP approach_NN ._SENT The_DT treatment_NN by_IN stratum_NN interaction_NN was_VBD investigated_VBN using_VBG the_DT Breslow-Day_JJ test_NN of_IN homogeneity_NN of_IN odds_NNS ratios_NNS and_CC the_DT Gail-Simon_NP test_NN ,_, if_IN needed_VBN ._SENT Kaplan-Meier_NP analyses_NNS were_VBD also_RB performed_VBN to_TO explore_VB the_DT time_NN to_TO DCIV_NP in_IN the_DT microbiologically_RB evaluable_JJ population_NN ._SENT The_DT SAS_NP ,_, version_NN 6.12_CD ,_, statistical_JJ package_NN was_VBD used_VBN for_IN analysis_NN ._SENT No_DT formal_JJ tests_NNS were_VBD performed_VBN based_VBN on_IN baseline_JJ demographics_NNS or_CC disease_NN characteristics_NNS ._SENT Patients_NNS ._SENT |_SYM The_DT distribution_NN of_IN the_DT study_NN patients_NNS is_VBZ summarized_VBN in_IN Fig._NN ._SENT A_DT total_NN of_IN 592_CD patients_NNS were_VBD randomized_VBN :_: 298_CD to_TO the_DT ertapenem_NN group_NN and_CC 294_CD to_TO the_DT ceftriaxone_NN group_NN ._SENT A_DT total_NN of_IN 159_CD (_( 53.4_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 171_CD (_( 58.2_CD %_NN )_) patients_NNS in_IN the_DT ceftriaxone_NN group_NN were_VBD microbiologically_RB evaluable_JJ ._SENT The_DT most_RBS common_JJ reason_NN patients_NNS were_VBD not_RB evaluable_JJ was_VBD failure_NN to_TO isolate_VB >=105_JJ CFU_NP of_IN a_DT uropathogen/ml_NN at_IN baseline_NN ._SENT Baseline_NN demographics_NNS and_CC disease_NN characteristics_NNS of_IN the_DT two_CD treatment_NN groups_NNS in_IN the_DT randomized_VBN and_CC microbiologically_RB evaluable_JJ populations_NNS were_VBD generally_RB similar_JJ ._SENT Approximately_RB 30_CD %_NN of_IN the_DT patients_NNS in_IN each_DT treatment_NN group_NN of_IN both_DT populations_NNS were_VBD male_JJ ._SENT In_IN the_DT evaluable_JJ population_NN ,_, 83_CD (_( 52.2_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 92_CD (_( 53.8_CD %_NN )_) patients_NNS in_IN the_DT ceftriaxone_NN group_NN had_VBD one_CD or_CC more_JJR urinary_JJ tract_NN abnormalities_NNS ;_: indwelling_VBG bladder_NN catheters_NNS or_CC stents_NNS were_VBD present_JJ in_IN 18_CD (_( 11.3_CD %_NN )_) and_CC 20_CD (_( 11.7_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN and_CC ceftriaxone_NN treatment_NN groups_NNS ,_, respectively_RB ._SENT Approximately_RB half_NN of_IN the_DT evaluable_JJ patients_NNS in_IN each_DT treatment_NN group_NN had_VBD severe_JJ infection_NN ._SENT Therapy_NN ._SENT |_SYM The_DT duration_NN of_IN parenteral_JJ ,_, oral_JJ ,_, and_CC total_JJ (_( parenteral_JJ plus_CC oral_JJ )_) study_NN therapy_NN in_IN the_DT treated_VBN and_CC microbiologically_RB evaluable_JJ patients_NNS was_VBD comparable_JJ in_IN the_DT ertapenem_NN and_CC ceftriaxone_NN treatment_NN groups_NNS ._SENT Of_IN the_DT evaluable_JJ patients_NNS ,_, 95.6_CD %_NN (_( 152_CD of_IN 159_CD )_) of_IN those_DT treated_VBN with_IN ertapenem_NN and_CC 94.7_CD %_NN (_( 162_CD of_IN 171_CD )_) of_IN those_DT treated_VBN with_IN ceftriaxone_NN were_VBD switched_VBN to_TO oral_JJ therapy_NN ,_, most_RBS commonly_RB ciprofloxacin_JJ (_( approximately_RB 94_CD %_NN in_IN each_DT treatment_NN group_NN )_) ._SENT The_DT Kaplan-Meier_NP curves_NNS for_IN the_DT time_NN to_TO the_DT switch_NN to_TO oral_JJ therapy_NN were_VBD similar_JJ for_IN ertapenem_NN and_CC ceftriaxone_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Most_JJS patients_NNS in_IN both_DT treatment_NN groups_NNS were_VBD switched_VBN to_TO oral_JJ therapy_NN by_IN study_NN day_NN 4_CD ._SENT Baseline_JJ microbiology_NN ._SENT |_SYM The_DT distribution_NN of_IN the_DT pathogens_NNS in_IN each_DT treatment_NN and_CC their_PP$ susceptibility_NN profiles_NNS were_VBD comparable_JJ ._SENT The_DT most_RBS frequently_RB isolated_VBN pathogen_NN was_VBD Escherichia_NP coli_NNS ,_, recovered_VBN from_IN 111_CD (_( 69.8_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 117_CD (_( 68.4_CD %_NN )_) patients_NNS in_IN the_DT ceftriaxone_NN group_NN ,_, followed_VBN by_IN Klebsiella_NP pneumoniae_NNS ,_, which_WDT was_VBD cultured_VBN from_IN 22_CD (_( 13.8_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 21_CD (_( 12.3_CD %_NN )_) patients_NNS in_IN the_DT ceftriaxone_NN group_NN ._SENT For_IN all_DT other_JJ species_NN ,_, there_EX were_VBD fewer_JJR than_IN 10_CD isolates_NNS per_IN group_NN ._SENT All_DT isolates_NNS were_VBD susceptible_JJ to_TO ertapenem_NN ,_, and_CC all_DT were_VBD susceptible_JJ or_CC intermediate_JJ to_TO ceftriaxone_NN ,_, with_IN the_DT exception_NN of_IN two_CD (_( 33.3_CD %_NN )_) of_IN six_CD enterococcus_NN isolates_NNS in_IN the_DT ertapenem_NN group_NN and_CC three_CD Pseudomonas_NP isolates_NNS (_( two_CD of_IN six_CD isolates_NNS in_IN the_DT ertapenem_NN group_NN and_CC one_CD of_IN two_CD isolates_NNS in_IN the_DT ceftriaxone_NN group_NN )_) ._SENT Twenty_CD microbiologically_RB evaluable_JJ patients_NNS who_WP received_VBD ertapenem_NN and_CC 15_CD patients_NNS treated_VBN with_IN ceftriaxone_NN were_VBD bacteremic_JJ at_IN the_DT baseline_NN ;_: the_DT etiologic_JJ agent_NN in_IN 27_CD (_( 75.0_CD %_NN )_) of_IN these_DT patients_NNS was_VBD E._NP coli_NNS ._SENT Efficacy_NN ._SENT |_SYM At_IN the_DT primary_JJ efficacy_NN endpoint_NN ,_, 91.8_CD %_NN of_IN the_DT microbiologically_RB evaluable_JJ patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 93.0_CD %_NN of_IN those_DT in_IN the_DT ceftriaxone_NN group_NN had_VBD a_DT favorable_JJ microbiologic_JJ response_NN assessment_NN (_( 95_CD %_NN CI_NP for_IN the_DT difference_NN ,_, adjusting_VBG for_IN strata_NNS ,_, -7.6_CD to_TO 5.1_CD %_NN )_) ,_, indicating_VBG equivalence_NN of_IN the_DT two_CD treatments_NNS ._SENT In_IN the_DT supportive_JJ microbiologic_JJ MITT_NP analysis_NN ,_, which_WDT included_VBD 80_CD %_NN of_IN all_DT patients_NNS randomized_VBD ,_, 92.5_CD %_NN treated_VBN with_IN ertapenem_NN and_CC 91.1_CD %_NN treated_VBN with_IN ceftriaxone_NN had_VBD a_DT favorable_JJ microbiologic_JJ response_NN (_( 95_CD %_NN CI_NP for_IN the_DT difference_NN ,_, -4.0_CD to_TO 6.9_CD %_NN )_) ,_, supporting_VBG the_DT results_NNS of_IN the_DT primary_JJ analysis_NN ._SENT Overall_JJ bacterial_JJ eradication_NN rates_NNS in_IN the_DT evaluable_JJ population_NN are_VBP summarized_VBN by_IN stratum_NN ,_, subgroup_NN ,_, and_CC time_NN of_IN assessment_NN (_( DCIV_NP and_CC the_DT TOC_NP visit_NN )_) in_IN Table_NP ._SENT There_EX were_VBD no_DT patients_NNS in_IN either_DT group_NN who_WP failed_VBD treatment_NN prior_RB to_TO receiving_VBG three_CD doses_NNS of_IN i.v._JJ therapy_NN ._SENT Eradication_NN rates_NNS by_IN pathogen_NN are_VBP shown_VBN in_IN Table_NP ._SENT One_CD persistent_JJ pathogen_NN (_( E._NP coli_NNS )_) in_IN the_DT ertapenem_NN group_NN developed_VBD resistance_NN to_TO the_DT oral_JJ study_NN drug_NN (_( ciprofloxacin_NN )_) ,_, none_NN had_VBD developed_VBN resistance_NN to_TO ertapenem_NN ._SENT In_IN the_DT ceftriaxone_NN group_NN ,_, one_CD persistent_JJ pathogen_NN (_( Citrobacter_NP freundii_NP )_) developed_VBD resistance_NN to_TO ceftriaxone_NN and_CC two_CD pathogens_NNS (_( Proteus_NP mirabilis_NP and_CC E._NP coli_NNS )_) had_VBD developed_VBN resistance_NN to_TO the_DT oral_JJ agent_NN (_( ciprofloxacin_NN )_) ._SENT Seventeen_CD of_IN the_DT 20_CD (_( 85.0_CD %_NN )_) bacteremic_JJ patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 13_CD of_IN the_DT 15_CD (_( 86.7_CD %_NN )_) in_IN the_DT ceftriaxone_NN group_NN had_VBD a_DT favorable_JJ overall_JJ microbiologic_JJ response_NN ._SENT Failures_NNS were_VBD a_DT result_NN of_IN persistent_JJ bacteriuria_NNS ;_: persistent_JJ bacteremia_NN was_VBD not_RB documented_VBN in_IN any_DT of_IN these_DT patients_NNS ._SENT Bacterial_JJ recurrence_NN rates_NNS in_IN patients_NNS evaluable_JJ for_IN the_DT LFU_NP assessment_NN (_( n_NN =_SYM 105_CD for_IN ertapenem_NN ;_: n_NN =_SYM 121_CD for_IN ceftriaxone_NN )_) were_VBD 7.6_CD %_NN of_IN patients_NNS treated_VBN with_IN ertapenem_NN and_CC 8.3_CD %_NN of_IN those_DT treated_VBN with_IN ceftriaxone_NN (_( 95_CD %_NN CI_NP for_IN the_DT difference_NN ,_, -8.7_CD to_TO 7.4_CD %_NN )_) ,_, indicating_VBG that_IN recurrence_NN rates_NNS in_IN the_DT two_CD treatment_NN groups_NNS were_VBD similar_JJ ._SENT In_IN the_DT ertapenem_NN group_NN none_NN of_IN these_DT recurrent_JJ pathogens_NNS had_VBD developed_VBN resistance_NN to_TO either_CC the_DT parenteral_JJ or_CC oral_JJ study_NN drug_NN ,_, whereas_IN one_CD recurrent_JJ pathogen_NN (_( E._NP coli_NNS )_) in_IN the_DT ceftriaxone_NN group_NN developed_VBD resistance_NN to_TO the_DT oral_JJ agent_NN (_( ciprofloxacin_NN )_) ._SENT Clinical_JJ relapse_NN rates_NNS at_IN the_DT LFU_NP visit_NN (_( 5.4_CD %_NN of_IN patients_NNS treated_VBN with_IN ertapenem_NP [_SYM n_NN =_SYM 114_CD ]_SYM and_CC 7.9_CD %_NN of_IN those_DT treated_VBN with_IN ceftriaxone_NP [_SYM n_NN =_SYM 135_CD ]_SYM )_) were_VBD also_RB similar_JJ ._SENT Nonbaseline_NP ,_, emergent_JJ infections_NNS included_VBD new_JJ infections_NNS ,_, which_WDT occurred_VBD in_IN 27_CD (_( 17.0_CD %_NN )_) microbiologically_RB evaluable_JJ patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 21_CD (_( 12.3_CD %_NN )_) patients_NNS in_IN the_DT ceftriaxone_NN group_NN ,_, and_CC superinfections_NNS ,_, which_WDT developed_VBD in_IN one_CD patient_NN in_IN each_DT treatment_NN group_NN ._SENT The_DT most_RBS common_JJ pathogens_NNS causing_VBG new_JJ infections_NNS in_IN both_DT groups_NNS were_VBD enterococci_NP ,_, E._NP coli_NNS ,_, and_CC K._NP pneumoniae_NNS ,_, in_IN descending_VBG order_NN of_IN frequency_NN ._SENT One_PP isolate_VBP each_DT of_IN Pantoea_NN agglomerans_NNS and_CC P._NP aeruginosa_NP was_VBD responsible_JJ for_IN superinfection_NN in_IN the_DT ertapenem_NN and_CC ceftriaxone_NN groups_NNS ,_, respectively_RB ._SENT Safety_NN and_CC local_JJ tolerability_NN ._SENT |_SYM A_DT total_NN of_IN 293_CD patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 289_CD patients_NNS in_IN the_DT ceftriaxone_NN group_NN received_VBD at_IN least_JJS one_CD dose_NN of_IN study_NN i.v._JJ therapy_NN and_CC were_VBD evaluated_VBN for_IN adverse_JJ experiences_NNS ._SENT During_IN i.v._JJ therapy_NN ,_, one_CD or_CC more_JJR drug-related_JJ adverse_JJ experiences_NNS were_VBD reported_VBN for_IN 86_CD (_( 29.4_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 76_CD (_( 26.3_CD %_NN )_) patients_NNS in_IN the_DT ceftriaxone_NN group_NN ,_, none_NN of_IN which_WDT was_VBD considered_VBN to_TO be_VB serious_JJ ._SENT The_DT most_RBS common_JJ drug-related_JJ adverse_JJ events_NNS in_IN the_DT treated_VBN population_NN were_VBD diarrhea_NN (_( ertapenem_NP ,_, 21_CD [_SYM 7.2_CD %_NN ]_SYM patients_NNS ;_: ceftriaxone_NN ,_, 19_CD [_SYM 6.6_CD %_NN ]_SYM patients_NNS )_) ,_, headache_NN (_( ertapenem_NP ,_, 19_CD [_SYM 6.5_CD %_NN ]_SYM patients_NNS ;_: ceftriaxone_NN ,_, 13_CD [_SYM 4.5_CD %_NN ]_SYM patients_NNS )_) ,_, and_CC nausea_NN (_( ertapenem_NP ,_, 16_CD [_SYM 5.5_CD %_NN ]_SYM patients_NNS ;_: ceftriaxone_NN ,_, 10_CD [_SYM 3.5_CD %_NN ]_SYM patients_NNS )_) ._SENT Parenteral_JJ study_NN therapy_NN was_VBD discontinued_VBN due_RB to_TO a_DT drug-related_JJ adverse_JJ experience_NN in_IN 8_CD (_( 2.7_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC none_NN in_IN the_DT ceftriaxone_NN group_NN ._SENT Events_NNS resulting_VBG in_IN discontinuation_NN of_IN ertapenem_NN were_VBD rash_JJ in_IN three_CD patients_NNS ,_, one_CD of_IN whom_WP reported_VBD a_DT prior_JJ penicillin_NN allergy_NN ,_, and_CC pruritus_NN ,_, vomiting_NN ,_, paresthesia_NN ,_, diarrhea_NN ,_, and_CC syncope_NN in_IN one_CD patient_NN each_DT ._SENT Drug-related_JJ laboratory_NN adverse_JJ experiences_NNS were_VBD reported_VBN in_IN 27_CD (_( 9.7_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 20_CD (_( 7.2_CD %_NN )_) patients_NNS in_IN the_DT ceftriaxone_NN group_NN ._SENT None_NN of_IN these_DT events_NNS was_VBD considered_VBN serious_JJ ,_, and_CC none_NN resulted_VBN in_IN discontinuation_NN of_IN study_NN therapy_NN ._SENT The_DT most_RBS common_JJ drug-related_JJ adverse_JJ laboratory_NN events_NNS were_VBD elevations_NNS of_IN alanine_NN aminotransferase_NN levels_NNS (_( 3.8_CD %_NN [_SYM 9_CD of_IN 240_CD patients_NNS ]_SYM in_IN the_DT ertapenem_NN group_NN and_CC 4.6_CD %_NN [_SYM 11_CD of_IN 238_CD patients_NNS ]_SYM in_IN the_DT ceftriaxone_NN group_NN )_) and_CC aspartate_JJ aminotransferase_NN levels_NNS (_( 3.7_CD %_NN [_SYM 10_CD of_IN 268_CD patients_NNS ]_SYM and_CC 3.4_CD %_NN [_SYM 9_CD of_IN 261_CD patients_NNS ]_SYM in_IN the_DT ertapenem_NN and_CC ceftriaxone_NN groups_NNS ,_, respectively_RB )_) ._SENT Twenty-seven_NP (_( 9.2_CD %_NN )_) patients_NNS in_IN the_DT ertapenem_NN group_NN and_CC 20_CD (_( 6.9_CD %_NN )_) patients_NNS in_IN the_DT ceftriaxone_NN group_NN experienced_VBD reactions_NNS of_IN moderate_JJ to_TO severe_JJ intensity_NN at_IN the_DT local_JJ infusion_NN site_NN ._SENT The_DT most_RBS common_JJ symptom_NN in_IN both_DT treatment_NN groups_NNS was_VBD pain_NN followed_VBN by_IN tenderness_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Profile_NP of_IN patient_JJ enrollment_NN ._SENT Profile_NN of_IN patient_JJ enrollment_NN ._SENT TABLE_NN 1_CD |_SYM Baseline_JJ characteristics_NNS and_CC therapy_NN of_IN randomized_VBN and_CC microbiologically_RB evaluable_JJ patients_NNS with_IN complicated_JJ UTI_NP TABLE_NP 2_CD |_SYM Favorable_JJ microbiologic_JJ response_NN assessments_NNS in_IN microbiologically_RB evaluable_JJ patients_NNS with_IN complicated_JJ UTI_NP TABLE_NP 3_CD |_SYM Eradication_NN rates_NNS at_IN TOC_NP in_IN microbiologically_RB evaluable_JJ patients_NNS with_IN complicated_JJ UTI_NP In_IN this_DT double-blind_JJ ,_, randomized_VBN study_NN ,_, the_DT efficacy_NN and_CC safety_NN of_IN ertapenem_NN were_VBD compared_VBN with_IN those_DT of_IN ceftriaxone_NN for_IN the_DT empirical_JJ treatment_NN of_IN serious_JJ complicated_JJ UTI_NN judged_VBN by_IN the_DT investigator_NN to_TO require_VB initial_JJ therapy_NN with_IN a_DT parenteral_JJ antimicrobial_JJ agent_NN ._SENT The_DT study_NN design_NN was_VBD consistent_JJ with_IN standard_JJ clinical_JJ practice_NN (_( -_: )_) ._SENT After_IN a_DT minimum_NN of_IN 3_CD full_JJ days_NNS of_IN parenteral_JJ study_NN therapy_NN ,_, investigators_NNS had_VBD the_DT option_NN to_TO switch_VB to_TO oral_JJ ciprofloxacin_NN (_( or_CC other_JJ agent_NN )_) if_IN the_DT patient_NN had_VBD clinically_RB improved_VBN ._SENT Approximately_RB 95_CD %_NN of_IN the_DT evaluable_JJ patients_NNS in_IN both_DT treatment_NN groups_NNS were_VBD switched_VBN to_TO oral_JJ therapy_NN (_( ciprofloxacin_NN in_IN about_RB 94_CD %_NN of_IN patients_NNS in_IN each_DT treatment_NN group_NN )_) ,_, usually_RB by_IN study_NN day_NN 4_CD ._SENT The_DT Kaplan-Meier_NP curves_NNS for_IN the_DT time_NN to_TO switch_VB to_TO oral_JJ therapy_NN in_IN the_DT microbiologically_RB evaluable_JJ population_NN appeared_VBD similar_JJ for_IN both_DT study_NN drugs_NNS ,_, indicating_VBG that_IN the_DT time_NN to_TO defervescence_NN and_CC improvement_NN of_IN clinical_JJ signs_NNS and_CC symptoms_NNS was_VBD comparable_JJ for_IN both_DT ertapenem_NN and_CC ceftriaxone_NN ._SENT Results_NNS of_IN this_DT study_NN show_VBP that_IN ertapenem_NN therapy_NN ,_, 1_CD g_NN once_IN a_DT day_NN ,_, was_VBD highly_RB effective_JJ in_IN all_DT patient_JJ populations_NNS ,_, including_VBG those_DT with_IN pyelonephritis_NN or_CC severe_JJ infection_NN and_CC the_DT elderly_JJ ,_, and_CC was_VBD equivalent_JJ to_TO treatment_NN with_IN ceftriaxone_NN ._SENT Over_IN 90_CD %_NN of_IN the_DT evaluable_JJ patients_NNS in_IN both_DT treatment_NN groups_NNS had_VBD a_DT favorable_JJ microbiologic_JJ response_NN assessment_NN at_IN the_DT TOC_NP visit_NN 5_CD to_TO 9_CD days_NNS posttherapy_NN ._SENT These_DT rates_NNS are_VBP similar_JJ to_TO or_CC better_JJR than_IN those_DT reported_VBN in_IN previous_JJ studies_NNS of_IN patients_NNS with_IN complicated_JJ UTIs_NP (_( -_: ,_, ,_, ,_, )_) ,_, and_CC they_PP exceed_VBP the_DT cure_NN rates_NNS expected_VBN when_WRB evaluating_VBG a_DT new_JJ anti-infective_JJ drug_NN for_IN the_DT treatment_NN of_IN UTI_NP (_( >80_JJ %_NN for_IN acute_JJ pyelonephritis_NN and_CC >65_NN %_NN for_IN complicated_JJ UTI_NP )_) ._SENT As_IN expected_VBN ,_, success_NN rates_NNS were_VBD higher_JJR at_IN the_DT completion_NN of_IN i.v._JJ therapy_NN than_IN at_IN the_DT TOC_NP visit_NN for_IN both_DT study_NN drugs_NNS ._SENT This_DT difference_NN was_VBD more_RBR apparent_JJ for_IN patients_NNS with_IN other_JJ complicated_JJ UTIs_NN than_IN for_IN those_DT with_IN acute_JJ pyelonephritis_NN ,_, which_WDT suggests_VBZ that_IN the_DT few_JJ additional_JJ failures_NNS posttherapy_NN were_VBD due_JJ to_TO the_DT underlying_VBG urinary_JJ tract_NN abnormality_NN or_CC inadequate_JJ oral_JJ therapy_NN rather_RB than_IN failure_NN of_IN the_DT parenteral_JJ antimicrobial_JJ agent_NN ._SENT Ertapenem_NP has_VBZ excellent_JJ activity_NN against_IN many_JJ gram-positive_JJ and_CC gram-negative_JJ aerobic_JJ ,_, facultative_JJ ,_, and_CC anaerobic_JJ bacteria_NNS generally_RB associated_VBN with_IN infections_NNS acquired_VBN in_IN the_DT community_NN ._SENT Several_JJ studies_NNS have_VBP shown_VBN that_IN most_JJS members_NNS of_IN the_DT family_NN Enterobacteriaceae_NNS are_VBP highly_RB susceptible_JJ to_TO ertapenem_NN ,_, including_VBG isolates_NNS resistant_JJ to_TO several_JJ other_JJ antimicrobial_JJ agents_NNS ._SENT In_IN this_DT study_NN ,_, members_NNS of_IN the_DT family_NN Enterobacteriaceae_NP ,_, all_DT of_IN which_WDT were_VBD susceptible_JJ to_TO ertapenem_NN ,_, accounted_VBN for_IN 93.0_CD %_NN of_IN all_DT isolates_NNS from_IN microbiologically_RB evaluable_JJ patients_NNS in_IN both_DT treatment_NN groups_NNS ._SENT Similar_JJ to_TO this_DT study_NN ,_, other_JJ studies_NNS have_VBP shown_VBN that_IN E._NP coli_NNS and_CC K._NP pneumoniae_NNS account_VBP for_IN the_DT majority_NN of_IN responsible_JJ pathogens_NNS in_IN complicated_JJ UTIs_NP ._SENT Ertapenem_NP is_VBZ thus_RB a_DT reasonable_JJ choice_NN for_IN treatment_NN of_IN complicated_JJ UTIs_NN when_WRB infection_NN is_VBZ not_RB caused_VBN by_IN P._NP aeruginosa_NP or_CC enterococci_NP ,_, both_DT of_IN which_WDT were_VBD recovered_VBN from_IN very_RB few_JJ patients_NNS in_IN this_DT study_NN ._SENT The_DT overall_JJ safety_NN and_CC tolerability_NN profile_NN of_IN ertapenem_NN in_IN this_DT study_NN was_VBD similar_JJ to_TO that_DT of_IN ceftriaxone_NN ._SENT Drug-related_JJ clinical_JJ adverse_JJ events_NNS most_RBS frequently_RB reported_VBN for_IN both_DT agents_NNS were_VBD related_VBN to_TO the_DT gastrointestinal_JJ tract_NN ._SENT The_DT most_RBS common_JJ drug-related_JJ laboratory_NN adverse_JJ event_NN for_IN both_DT drugs_NNS was_VBD mild_JJ to_TO moderate_JJ elevation_NN of_IN transaminase_NN levels_NNS ,_, which_WDT tended_VBD to_TO be_VB transient_JJ and_CC without_IN clinical_JJ consequence_NN ._SENT In_IN summary_NN ,_, in_IN adult_NN patients_NNS with_IN moderate_JJ to_TO severe_JJ complicated_JJ UTI_NP requiring_VBG initial_JJ parenteral_JJ therapy_NN ,_, ertapenem_NN (_( 1_CD g_NN once_IN a_DT day_NN )_) ,_, with_IN the_DT option_NN to_TO switch_VB to_TO an_DT appropriate_JJ oral_JJ antimicrobial_JJ agent_NN after_IN clinical_JJ improvement_NN ,_, was_VBD generally_RB well_RB tolerated_VBN and_CC highly_RB effective_JJ both_CC clinically_RB and_CC microbiologically_RB ._SENT 